Efficacy of 5-HT 3 antagonists and 5-HT 4 agonists in irritable bowel syndrome: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1831-1843

  Ford, Alexander C ^a,e   Brandt, Lawrence J ^b   Young, Christine ^a   Chey, William D ^c   Foxx Orenstein, Amy E ^d   Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d MAYO CLINIC   (United States)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; CILANSETRON; CISAPRIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RENZAPRIDE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TEGASEROD; CARBAZOLE DERIVATIVE; CARBOLINE DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTINUING EDUCATION; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; STOMACH MOTILITY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; AGE; AGED; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; MALE; MEDICAL EDUCATION; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; CARBAZOLES; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PATIENT SATISFACTION; PYRIDINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 67650455908     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.223     Document Type: Article

References (59)

1. Agreus L, Talley NJ, Svardsudd K et al. Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors . Scand J Gastroenterol 2000 ; 35 : 142-5.
2. Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population . Aliment Pharmacol Ther 2004;20:339-45.
3. Hungin APS, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects . Aliment Pharmacol Ther 2003;7:643-50.
4. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders . Gastroenterology 2006 ; 130 : 1480-91.
5. Cann PA, Read NW, Brown C et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns . Gut 1983;24:405-11.
6. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility . Dig Dis Sci 1993 ; 38 : 1761-2.
7. Moriarty KJ, Dawson AM. Functional abdominal pain: further evidence that whole gut is affected . Br Med J 1982 ; 284 : 1670-2
8. Trimble KC, Farouk R, Pryde A et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity . Dig Dis Sci 1995 ; 40 : 1607-3.
9. Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior . Am J Gastroenterol 2008 ; 103 : 1229-39.
10. Talley NJ, Gabriel SE, Harmsen WS et al. Medical costs in community subjects with irritable bowel syndrome . Gastroenterology 1995 ; 109 : 1736-41.
11. Wilson S, Roberts L, Roalfe A et al. Prevalence of irritable bowel syndrome: a community survey . Br J Gen Pract 2004 ; 54 : 495-502.
12. Atkinson W, Lockhart S, Whorwell PJ et al. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43.
13. Anonymou s. Glaxo Wellc ome withdraws irritable bowel syndrome medication. FDA Consum 2001;35:3.
14. Chang L, Chey WD, Harris L et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-surveillance marketing data . Am J Gastroenterol 2006 ; 101 : 1069-79.
15. FDA Public Health Advisory: Tegaserod Maleate (Marketed as Zelnorm). http://www fda gov/cder/drug/advisory/tegaserod htm . 2007 .
16. Cremonini F, Delgado-Aros S, Camilleri M. Effcacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials . Neuro-gastroenterol Motil 2003;15:79-86.
17. Evans BW, Clark WK, Moore DJ et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation . Cochrane Database Syst Rev 2007 ; 17 : CD003960 .
18. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum A Meta-analysis: the treatment of irritable bowel syndrome . Aliment Pharmacol Ther 2004 ; 20 : 1253-69.
19. Jones BW, Moore DJ, Robinson SM et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome . J Clin Pharmacol 2002 ; 27 : 343-52.
20. Rahimi R, Nikfar S, Abdollahi M. Effcacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials . Clin Ther 2008;30:884-901.
21. Andresen V, Montori VM, Keller J et al. Efects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in noncon-stipated irritable bowel syndrome: a systematic review and meta-analysis of randomised controlled trials . Clin Gastroenterol Hepatol 2008 ; 6 : 545-55.
22. American College of Gastroenterology IBS Task Force. An evidence-based position statement on the management of irritable bowel syndrome . Am J Gastroenterol 2009 ; 104 (Suppl I) : S1-7.
23. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based systematic review on the management of irritable bowel syndrome . Am J Gastroenterol 2009 ; 104 (Suppl I) : S8-S35.
24. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 996;17:1-12.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials . Control Clin Trials 986;7:177-88.
26. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses . Br Med J 2003 ; 327 : 557-60.
27. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test . Br Med J 1997 ; 315 : 629-34.
28. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT 3 receptor antagonist . Aliment Pharmacol Ther 1999 ; 13 : 1149-59.
29. Lembo T, Wright RA, Bagby B, et al., Lotronex Investigator Team . Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome . Am J Gastroenterol 2001 ; 96 : 2662-70.
30. Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome . Aliment Pharmacol Ther 2000;14:23-34.
31. Camilleri M, Northcutt AR, Kong S et al. Effcacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial . Lancet 2000 ; 355 : 1035-40.
32. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome . Arch Intern Med 2001 ; 161 : 1733-40.
33. Krause R, Ameen V, Gordon SH et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS . Am J Gastroenterol 2007 ; 102 : 1709-19.
34. Chang L, Ameen VZ, Dukes GE et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS . Am J Gastroenterol 2005 ; 100 : 115-23.
35. Chey WD, Chey WY, Heath AT et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome . Am J Gastroenterol 2004 ; 99 : 2195-203.
36. Bradette M, Moennikes H, Carter F et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study . Gastroenterology 2004 ; 126 (Suppl 2) : A42 .
37. Francisconi CF, Drossman DA, Mayer EA et al. Interruption of daily activities in cilansetron-treated patients with irritable bowel syndrome with diarrhea-predominance (IBS-D): results from a 16-week, placebo-controlled, rerandomization trial . Gastroenterology 2006 ; 130 (Suppl 2) : A600 .
38. Miner P, Stanton D, Carter F et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 3 month US study . Am J Gastroenterol 2004 ; 99 (Suppl) : S277 .
39. 4receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation . Aliment Pharmacol Ther 2001 ; 15 : 1655-66.
40. Tack J, Muller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation . Gut 2005 ; 54 : 1707-13.
41. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation . Aliment Pharmacol Ther 2002 ; 16 : 1877 -88 .
42. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome . Gut 2003 ; 52 : 671-6.
43. Harish K, Hazeena K, Varghese T et al. Efect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome . J Gastroenterol Hepatol 2007 ; 22 : 1183-9.
44. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome . Scand J Gastroenterol 2004;39:119-26.
45. 4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS) . Digestion 1998 ; 59 (Suppl 3) : 735 .
46. Novartis Pharmaceuticals Corporation . Zelmac ™ (tegaserod) advisory committee briefing document . www fda gov/ohrms/dockets/ac/00/backgrd/ 3627b1a pdf, Accessed 20 July 2008 2000 .
47. Spiller RC, Meyers NL, Hickling RI. Identifcation of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial . Dig Dis Sci 2008 ; 53 : 3191-200.
48. Camilleri M, McKinzie S, Fox J et al. Efect of renzapride on transit in constipation-predominant irritable bowel syndrome . Clin Gastroenterol Hepatol 2004;2:895-904.
49. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting . Aliment Pharmacol Ther 2008;27:830-7.
50. Schutze K, Brandstatter G, Dragosics B et al. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome . Aliment Pharmacol Ther 1997;11:387-94.
51. Van Outryve M, Milo R, Toussaint J et al. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride . J Clin Gastroenterol 1991 ; 13 : 49-57.
52. Ziegenhagen DJ, Kruis W. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo . J Gastroenterol Hepatol 2004;19:744-9.
53. Farup PG, Hovdenak N, Wetterhus S et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation . Scand J Gastroenterol 1998 ; 33 : 128-3.
54. Chey WD, Pare P, Viegas A et al. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial . Am J Gastroenterol 2008 ; 103 : 1217-25.
55. 4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS) . Digestion 1998 ; 59 (Suppl 3) : 20 .
56. Veldhuyzen Van Zanten SJ, Talley NJ, Bytzer P et al. Design of treatment trials for functional gastrointestinal disorders . Gut 1999 ; 45 (Suppl II) : II69-77.
57. Roelofs PD, Deyo RA, Koes BW et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review . Spine 2008 ; 33 : 1766 -74 .
58. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myo-cardial infarction among users of rofecoxib, celecoxib, and other NSAIDs . Arch Intern Med 2005;165:978-84.
59. Moore RA, Derry S, Phillips CJ et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice . BMC Musculoskelet Disord 2006;7:79.